Healthy Participants Clinical Trial
Official title:
Is There a Dose-response Effect on Bone Characteristics in Relation to Drop Jump Height?
Verified date | February 2024 |
Source | Nottingham Trent University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study aims to assess if a 16-week drop jump intervention from different heights shows different bone adaptations. Participants will complete four visits over a period of 16 weeks. An initial consultation will be conducted to ensure participants meet the inclusion criteria following participant recruitment. Estimated load being applied to the bone, will be assessed using non-invasive biomechanical procedures (Inertial Measurement Units, motion analysis, force plates) during drop jumps. Participants will be assigned a drop jump height of 0 cm, 30 cm or 60 cm based on a significant difference in external load at these heights or assigned to a control group where no jumps will be performed. Groups will be matched for body mass to ensure that jump height produces the load. The participants will be asked to perform 40 jumps (20 each side), 4 times per week ensuring jumping bouts are separated by 24 hours. Bone characteristics will be assessed via whole body dual-energy X-ray absorptiometry (DXA) scans and bilateral peripheral Quantitative Computed Tomography (pQCT) scans. Lab based jumping will take place on week 0, week 6, week 12, and week 16 to understand the loading applied during the different jump height groups. pQCT scans will take place on week 0, week 12, week 16 and DXA scans will take place week 0 and week 16. The reasoning of week 12 for pQCT being it may show a significant timepoint for bone formation during the remodelling cycle. During visits participants will complete a health screen, the Bone specific Physical Activity Questionnaire (BPAQ), a food frequency questionnaire and Pittsburgh sleep quality questionnaire alongside consent as tools to monitor any changes to participant lifestyle across the study. Differences in bone characteristics, lab measures and jump heights will be analysed between and within participants. The present study aims to use varied drop jump heights to identify an osteogenic dose response effect. Drop jumps have been previously used to expose osteogenic effects in research due to the load produced at impact. Is it possible to identify an optimum height for bone response during impact? If so do we then find anything above this height actually has negative or no effect on a group of individuals?
Status | Completed |
Enrollment | 48 |
Est. completion date | December 13, 2023 |
Est. primary completion date | December 13, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 25 Years |
Eligibility | Inclusion Criteria: - 18 to 25 years old - Have a low physical activity status defined as partaking in physical training activities no more than 2x per week. - No current regular participation (more than once per week) in exercise programmes known to influence bone inc. gymnastics, dance, court sports, ball sports or racquet sports. - Be able to travel to the laboratory using a vehicle or public transport - Have the ability to comprehend and understand communication and instruction in English in order to consent and safely participate in study. - Have no current unresolved cardiovascular complaints to avoid any cardiovascular complications when performing activities of daily living. Exclusion Criteria: - Prescribed medication that influences bone metabolism such as corticosteroids, anticancer drugs, and diabetes related Drugs - Joint replacement or prostheses - Currently or recently injured - Medical conditions adversely affected by exposure to ionising radiation. - History of high levels of ionising radiation exposure (e.g., medical treatment). - Breastfeeding women, pregnant women and women trying to become pregnant - Females who are on any form of contraception that may influence changes in bone - Females who have current or previous history of an endocrine disorder |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Nottingham Trent University | Nottingham | Nottinghamshire |
Lead Sponsor | Collaborator |
---|---|
Nottingham Trent University |
United Kingdom,
Kenkre JS, Bassett J. The bone remodelling cycle. Ann Clin Biochem. 2018 May;55(3):308-327. doi: 10.1177/0004563218759371. Epub 2018 Mar 4. — View Citation
Min SK, Oh T, Kim SH, Cho J, Chung HY, Park DH, Kim CS. Position Statement: Exercise Guidelines to Increase Peak Bone Mass in Adolescents. J Bone Metab. 2019 Nov;26(4):225-239. doi: 10.11005/jbm.2019.26.4.225. Epub 2019 Nov 30. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | BMD as assessed by whole body dual-energy X-ray absorptiometry (DXA). | Bone mineral density (BMD) | From baseline (week 0) to end of intervention (week 16) | |
Primary | BMC as assessed by whole body dual-energy X-ray absorptiometry (DXA). | Bone mineral content (BMC) | From baseline (week 0) to end of intervention (week 16) | |
Primary | Total bone area as assessed by whole body dual-energy X-ray absorptiometry (DXA). | Total bone area | From baseline (week 0) to end of intervention (week 16) | |
Primary | Trabecular density as assessed by peripheral quantitative tomography (pQCT) of tibia. | Trabecular density measured at the 4% site of the tibia length. | From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16) | |
Primary | Cortical thickness as assessed by peripheral quantitative tomography (pQCT) of tibia. | Cortical thickness measured at the 14% and 38% site of the tibial length. | From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16) | |
Primary | Periosteal circumference as assessed by peripheral quantitative tomography (pQCT) of tibia. | Periosteal circumference measured at the 14% and 38% site of the tibial length. | From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16) | |
Primary | Axial bone strength (SSIX) as assessed by peripheral quantitative tomography (pQCT) of tibia. | SSIX measured at the 14% and 38% site of the tibial length. | From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16) | |
Primary | Axial bone strength (SSIY) as assessed by peripheral quantitative tomography (pQCT) of tibia. | SSIY measured at the 14% and 38% site of the tibial length. | From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16) | |
Primary | Polar bone strength (SSIPOL) as assessed by peripheral quantitative tomography (pQCT) of tibia. | SSIPOL measured at the 14% and 38% site of the tibial length. | From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16) | |
Primary | Cortical density as assessed by peripheral quantitative tomography (pQCT) of tibia. | Cortical density measured at the 14%, 38% and 66% site of the tibial length. | From baseline (week 0) to mid intervention (week 12) and end of intervention (week 16) | |
Secondary | Peak impact load as assessed by force plates. | Peak impact load derived from ground reaction force (GRF) | From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16) | |
Secondary | Impulse as assessed by force plates. | Impulse derived from ground reaction force (GRF) | From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16) | |
Secondary | Load rate as assessed by force plates. | Load rate derived from ground reaction force (GRF) | From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16) | |
Secondary | Jump height as assessed by force plates. | Jump height derived from ground reaction force (GRF) | From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16) | |
Secondary | Centre of Mass (CoM) velocity as assessed by force plates. | CoM velocity derived from ground reaction force (GRF) | From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16) | |
Secondary | Peak acceleration as assessed by Inertial measurement units (IMU). | Peak accelerations calculated from tibial mounted IMUs. | From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16) | |
Secondary | Stiffness as assessed by motion capture. | Knee and ankle Stiffness derived from motion capture. | From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16) | |
Secondary | Moments as assessed by motion capture. | Knee and ankle moments derived from motion capture. | From baseline (week 0) to mid intervention (week 6, week 12) and end of intervention (week 16) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05445440 -
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine
|
Phase 1 | |
Completed |
NCT03712540 -
An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants
|
Phase 1 | |
Completed |
NCT03649165 -
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT05956002 -
A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants
|
Phase 1 | |
Completed |
NCT05539976 -
A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants
|
||
Withdrawn |
NCT04558216 -
Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
|
Phase 1 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT06097390 -
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
|
Phase 1 | |
Completed |
NCT05546151 -
A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent
|
Phase 1 | |
Completed |
NCT05056246 -
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
|
Phase 1 | |
Completed |
NCT04390776 -
Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.
|
Phase 1 | |
Completed |
NCT05074459 -
A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines
|
Phase 1 | |
Enrolling by invitation |
NCT06089109 -
Creating VIP Corps to Reduce Maternal Deaths
|
N/A | |
Completed |
NCT05996250 -
Tolerance of an Immersive Virtual Reality Task Evaluating the Spatial Memory of Elderly Subjects
|
N/A | |
Completed |
NCT03278080 -
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1
|
N/A | |
Completed |
NCT05064800 -
PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
|
Phase 1 | |
Completed |
NCT04471298 -
A Study of Qishenyiqi Dripping Pills in Healthy Participants
|
Phase 1 | |
Completed |
NCT04914936 -
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
|
Phase 1 | |
Completed |
NCT02882386 -
Amino Acid Kinetics in Blood After Consuming Different Milk Protein Supplements
|
N/A | |
Completed |
NCT01681186 -
A Study of LY2940680 in Healthy Participants
|
Phase 1 |